What a breast biopsy is, and what it is like

Being told you need a biopsy is not the same as being told you have cancer. Most breast biopsies come back benign, and the ones that do not come back with the information that shapes the whole plan.

What a core needle biopsy is like

Nearly all breast biopsies are done through numbed skin, guided by ultrasound, by mammogram, or occasionally by MRI. It takes well under an hour and you go home afterward with a small dressing. A tiny metal is left at the spot so that it can be found again. The clip is harmless, does not set off airport security, and stays in place for good if nothing further is needed.

How long biopsy results take

The first answer, benign or not, usually comes within a few business days. If it is cancer, the lab then runs the receptor tests, and those can take about another week. It is normal for the information to arrive in pieces.

The four kinds of answer

A biopsy comes back as one of the following, and each has its own page:

Benign, or benign but high risk, which includes cysts, fibroadenomas, and findings such as atypical cells that raise future risk without being cancer.
DCIS, cancer cells that are still inside the milk duct.
Invasive breast cancer, which is sorted further by its receptors: hormone receptor positive, HER2 positive, or triple negative.
Occasionally, not enough tissue to be sure, in which case the biopsy is repeated or a small operation removes the whole area.

In plain terms

The biopsy tells you what it is. The receptor tests, about a week later, tell you what it responds to. The plan is built from both, which is why the first appointment after a diagnosis often comes with some results still pending.

Benign and high-risk findings

Most biopsies end here. means not cancer. A few benign findings still matter, either because the area should come out or because they raise your risk of a cancer in the future and change how closely you are watched. Dr. Perkins sees benign breast concerns and high-risk monitoring as part of her practice, so none of these is too small to bring in.

The benign and high-risk findings, one by one

Cysts are fluid-filled pockets. Simple cysts are harmless and are usually left alone unless they hurt, in which case they can be drained.
are smooth, rubbery lumps of normal breast tissue, most common in younger women. They are usually watched, and removed if they grow or bother you.
are small growths inside a duct, often the cause of clear or bloody discharge from one nipple. They are usually removed, because a small number contain atypical cells.
are not scars at all but a pattern of tissue that can look like cancer on a mammogram. They are often removed to be sure.
, written ADH or ALH, means cells that are growing more than they should and look abnormal, without being cancer. It raises future risk. When found on a needle biopsy, the area is usually removed with a small operation, because a needle samples only part of it.
, lobular carcinoma in situ, has the word carcinoma in its name but is not treated as a cancer. It is a marker that raises the risk of a future cancer in either breast.

What usually happens next after a benign result

For a simple cyst or a typical fibroadenoma, usually nothing beyond a follow-up picture. For a papilloma, radial scar, atypical hyperplasia, or some forms of LCIS, a small operation to remove the area so the whole thing can be examined. For atypical hyperplasia and LCIS, a conversation about risk: your lifetime risk gets estimated, and if it is high, screening may add a yearly , and a daily pill that lowers risk, such as , may be offered.

Choices you may be asked about after a benign result

Whether to remove or watch a fibroadenoma. Whether to take a risk-lowering medicine, which is a trade between fewer future cancers and side effects. Whether to add MRI to your screening. None of these has a single right answer, which is why they are choices.

In plain terms

High risk means more watching, not more treatment. The point of finding these is to catch anything that does develop while it is small.

If the biopsy finds cancer

The biopsy report names the type, and about a week later the receptor tests say what it responds to. The pathology report page turns the words on the report into plain language and builds a list of questions to bring, and each diagnosis has its own page: DCIS, hormone receptor positive, HER2 positive, triple negative, and lobular.

Where this comes from

Sources, checked 9 September 2026

This page is written in plain language from the current NCCN Guidelines for Patients: Invasive Breast Cancer (2026 edition, based on NCCN Guidelines for Breast Cancer version 2.2026), which Dr. Perkins shared as the reference for this page and which is free to read at NCCN.org/patientguidelines, along with NCCN's separate patient guides for DCIS and for metastatic breast cancer. NCCN's material is copyrighted and nothing here reproduces it; readers who want the full detail should go to the source. Breastcancer.org publishes a free guide to reading a pathology report, updated June 2026, at breastcancer.org/pathology-report. Margin definitions follow the Society of Surgical Oncology and American Society for Radiation Oncology consensus statements for invasive cancer (2014) and DCIS (2016). Receptor cutoffs follow the American Society of Clinical Oncology and College of American Pathologists guidelines. Staging follows the American Joint Committee on Cancer, eighth edition. Every clinical statement on this page is listed on the site's verification ledger, and Dr. Perkins read the site on 13 September 2026.

This page is education. It does not diagnose, and the summary it builds is not a treatment plan. Your plan is made with your own care team from your own results.

Published 7 September 2026 as part of the guide; a page of its own since 9 September 2026.

If a biopsy is recommended, and what the results can mean